The WHO Expert Committee on Biological Standardization convened in Geneva from October 12 to 16, 2015, to address crucial matters concerning the quality, safety, and efficacy of biological medicines. The overarching aim of the Committee's work is to foster global consensus on technical standards, thereby promoting convergent regulatory decision-making across nations and ensuring the consistent application of these vital standards worldwide.
Central to the report are the discussions surrounding the development and adoption of new and revised WHO Recommendations, Guidelines, and various guidance documents, all of which hold significant relevance for both manufacturers and national regulatory authorities. These deliberations are fundamental to shaping the global landscape of biological product regulation.
Among the key adoptions was a WHO guidance document dedicated to the regulatory assessment of approved rDNA-derived biotherapeutics. This document provides essential direction for evaluating these advanced therapeutic products. Additionally, the Committee adopted new WHO Guidelines on the stability evaluation of vaccines, particularly those intended for use under extended controlled temperature conditions, alongside updated WHO good manufacturing practices specifically tailored for biological products.
A significant revision also saw the adoption of updated WHO Recommendations designed to assure the quality, safety, and efficacy of recombinant human papillomavirus (HPV) virus-like particle vaccines. These revisions were prompted by the substantial data accumulated during vaccine implementation, the emergence of prophylactic vaccines with broader valency, and the evolution of production methods. The scope of these recommendations specifically covers recombinant HPV VLP vaccines for prophylactic use containing the L1 capsid protein.
Beyond these specific adoptions, the report delves into the current status and proposed future development of international reference materials. This encompasses a broad spectrum of biological substances, including antibiotics, biotherapeutics other than blood products, blood products and related substances, in vitro diagnostic device reagents, and vaccines and their associated components.
The comprehensive nature of the report is further underscored by its annexes, which include an updated list of all WHO Recommendations, Guidelines, and other pertinent documents concerning biological substances utilized in medicine. The four key WHO documents adopted during the Committee's session are also published in full within these annexes, providing detailed guidance for global implementation.
